Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California. more
Time Frame | SGMT | Sector | S&P500 |
---|---|---|---|
1-Week Return | 12.76% | -2.12% | -3% |
1-Month Return | 9.51% | -3.42% | -0.73% |
3-Month Return | 57.64% | -11.13% | 2.87% |
6-Month Return | 27.25% | -5.74% | 7.17% |
1-Year Return | -7.99% | 3.97% | 25.31% |
3-Year Return | -68.97% | 1.05% | 28.38% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | 2.00M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | - | 124.00K | 134.00K | 130.00K | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":92.54,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":97.01,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Profit | - | (124.00K) | (134.00K) | (130.00K) | 2.00M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-6.2,"profit":false},{"date":"2021-12-31","value":-6.7,"profit":false},{"date":"2022-12-31","value":-6.5,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | - | (Infinity%) | (Infinity%) | (Infinity%) | 100.00% | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 14.25M | 11.40M | 23.72M | 31.05M | 32.74M | [{"date":"2019-12-31","value":43.53,"profit":true},{"date":"2020-12-31","value":34.82,"profit":true},{"date":"2021-12-31","value":72.45,"profit":true},{"date":"2022-12-31","value":94.85,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (14.25M) | (11.40M) | (23.72M) | (31.05M) | (30.74M) | [{"date":"2019-12-31","value":-1425200000,"profit":false},{"date":"2020-12-31","value":-1140000000,"profit":false},{"date":"2021-12-31","value":-2371900000,"profit":false},{"date":"2022-12-31","value":-3105500000,"profit":false},{"date":"2023-12-31","value":-3074000000,"profit":false}] |
Total Non-Operating Income/Expense | (9.00K) | 60.00K | (723.00K) | 556.00K | 4.60M | [{"date":"2019-12-31","value":-0.2,"profit":false},{"date":"2020-12-31","value":1.3,"profit":true},{"date":"2021-12-31","value":-15.71,"profit":false},{"date":"2022-12-31","value":12.08,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (14.26M) | (11.37M) | (24.44M) | (30.50M) | (27.88M) | [{"date":"2019-12-31","value":-1426100000,"profit":false},{"date":"2020-12-31","value":-1137000000,"profit":false},{"date":"2021-12-31","value":-2444200000,"profit":false},{"date":"2022-12-31","value":-3049900000,"profit":false},{"date":"2023-12-31","value":-2787600000,"profit":false}] |
Income Taxes | (9.00K) | (176.30K) | (23.75M) | (31.61M) | (2.86M) | [{"date":"2019-12-31","value":-900000,"profit":false},{"date":"2020-12-31","value":-17629700,"profit":false},{"date":"2021-12-31","value":-2374500000,"profit":false},{"date":"2022-12-31","value":-3160800000,"profit":false},{"date":"2023-12-31","value":-286000000,"profit":false}] |
Income After Taxes | (14.25M) | (11.19M) | (697.00K) | 1.11M | (25.02M) | [{"date":"2019-12-31","value":-1285.12,"profit":false},{"date":"2020-12-31","value":-1009.35,"profit":false},{"date":"2021-12-31","value":-62.85,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-2255.73,"profit":false}] |
Income From Continuous Operations | (14.26M) | (11.37M) | (24.44M) | (30.50M) | (26.92M) | [{"date":"2019-12-31","value":-1426100000,"profit":false},{"date":"2020-12-31","value":-1137000000,"profit":false},{"date":"2021-12-31","value":-2444200000,"profit":false},{"date":"2022-12-31","value":-3049900000,"profit":false},{"date":"2023-12-31","value":-2692000000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (14.26M) | (11.37M) | (24.44M) | (30.50M) | (27.88M) | [{"date":"2019-12-31","value":-1426100000,"profit":false},{"date":"2020-12-31","value":-1137000000,"profit":false},{"date":"2021-12-31","value":-2444200000,"profit":false},{"date":"2022-12-31","value":-3049900000,"profit":false},{"date":"2023-12-31","value":-2787600000,"profit":false}] |
EPS (Diluted) | - | - | - | - | (37.37) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-3737,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
SGMT | |
---|---|
Cash Ratio | 37.26 |
Current Ratio | 38.41 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
SGMT | |
---|---|
ROA (LTM) | -21.54% |
ROE (LTM) | -29.32% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
SGMT | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.02 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.98 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
SGMT | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 81.62 |
P/B | 0.96 |
Price/FCF | NM |
EV/R | 0.28 |
EV/Ebitda | NM |
Sagimet Biosciences Inc. Series A Common Stock (SGMT) share price today is $4.95
Yes, Indians can buy shares of Sagimet Biosciences Inc. Series A Common Stock (SGMT) on Vested. To buy Sagimet Biosciences Inc. Series A Common Stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SGMT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Sagimet Biosciences Inc. Series A Common Stock (SGMT) via the Vested app. You can start investing in Sagimet Biosciences Inc. Series A Common Stock (SGMT) with a minimum investment of $1.
You can invest in shares of Sagimet Biosciences Inc. Series A Common Stock (SGMT) via Vested in three simple steps:
The 52-week high price of Sagimet Biosciences Inc. Series A Common Stock (SGMT) is $20.71. The 52-week low price of Sagimet Biosciences Inc. Series A Common Stock (SGMT) is $2.39.
The price-to-earnings (P/E) ratio of Sagimet Biosciences Inc. Series A Common Stock (SGMT) is
The price-to-book (P/B) ratio of Sagimet Biosciences Inc. Series A Common Stock (SGMT) is 0.96
The dividend yield of Sagimet Biosciences Inc. Series A Common Stock (SGMT) is 0.00%
The market capitalization of Sagimet Biosciences Inc. Series A Common Stock (SGMT) is $191.24M
The stock symbol (or ticker) of Sagimet Biosciences Inc. Series A Common Stock is SGMT